

参考文献:

- [1] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华传染病杂志, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050. Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2022 version) [J]. Chin J Infect, 2023, 41(1): 3-28. DOI: 10.3760/cma.j.cn311365-20230220-00050.
- [2] Lau G, Yu M L, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy[J]. Hepatol Int, 2021, 15(5): 1031-1048. DOI: 10.1007/s12072-021-10239-x.
- [3] Ali F S, Nguyen M H, Hernaez R, et al. AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals[J]. Gastroenterology, 2025, 168(2): 267-284. DOI: 10.1053/j.gastro.2024.11.008.
- [4] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2025, 83(2): 502-583. DOI: 10.1016/j.jhep.2025.03.018.
- [5] 陈耀龙, 杨克虎, 王小钦, 等. 中国制订/修订临床诊疗指南的指导原则(2022版)[J]. 中华医学杂志, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911. Chen Yaolong, Yang Kehu, Wang Xiaoqin, et al. Guiding principles for the development/revision of clinical diagnosis and treatment guidelines in China (2022 Edition) [J]. Natl Med J China, 2022, 102(10): 697-703. DOI: 10.3760/cma.j.cn112137-20211228-02911.
- [6] 中国医药生物技术协会药物性肝损伤防治技术专业委员会, 中华医学会肝病学分会药物性肝病学组. 中国药物性肝损伤防治指南(2023年版)[J]. 胃肠病学, 2023, 28(7): 397-431. DOI: 10.3760/cma.j.cn501113-20230419-00176. Technology Committee on DILI Prevention and Management, Chinese Medical Biotechnology Association; Study Group of Drug-Induced Liver Disease, Chinese Medical Association for the Study of Liver Diseases. Chinese guideline for diagnosis and management of drug-induced liver injury(2023 version) [J]. Chin J Gastroenterol, 2023, 28(7): 397-431. DOI: 10.3760/cma.j.cn501113-20230419-00176.
- [7] Yang Y T, Huang A L, Zhao Y. Effect of hepatitis B surface antibody in patients with core antibody-positive liver transplantation: A systematic review and meta-analysis[J]. Hepatol Int, 2020, 14(2): 202-211. DOI: 10.1007/s12072-020-10021-5.
- [8] Zhang A B, Wu Y B, Tan Y M, et al. Determining whether prophylactic antiviral treatment is necessary in HBsAg-negative/HBcAb-positive patients receiving allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(5): 956-964. DOI: 10.1016/j.bbmt.2020.01.006.
- [9] Wu T, Wu N, Ma Y X, et al. Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients[J]. Antiviral Res, 2020, 177: 104765. DOI: 10.1016/j.antiviral.2020.104765.
- [10] Li P, Zhou L L, Ye S G, et al. Risk of HBV reactivation in patients with resolved HBV infection receiving anti-CD19 chimeric antigen receptor T cell therapy without antiviral prophylaxis[J]. Front Immunol, 2021, 12: 638678. DOI: 10.3389/fimmu.2021.638678.
- [11] Buonomo A R, Viceconte G, Calabrese M, et al. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: A multicentric Italian retrospective study[J]. J Neurol, 2022, 269(6): 3301-3307. DOI: 10.1007/s00415-022-11009-x.
- [12] Wong G L, Wong V W, Yuen B W, et al. Risk of hepatitis B surface antigen seroreversion after corticosteroid treatment in patients with previous hepatitis B virus exposure[J]. J Hepatol, 2020, 72(1): 57-66. DOI: 10.1016/j.jhep.2019.08.023.
- [13] Xuan D D, Yu Y Q, Shao L Y, et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy: A report of long-term follow-up of serial cases and literature review[J]. Clin Rheumatol, 2014, 33(4): 577-586. DOI: 10.1007/s10067-013-2450-9.
- [14] Zhong Z Y, Liao W T, Dai L Y, et al. Average corticosteroid dose and risk for HBV reactivation and hepatitis flare in patients with resolved hepatitis B infection[J]. Ann Rheum Dis, 2022, 81(4): 584-591. DOI: 10.1136/annrheumdis-2021-221650.
- [15] Pei S N, Chen C H, Lee C M, et al. Reactivation of hepatitis B virus following rituximab-based regimens: A serious complication in both HBsAg-positive and HBsAg-negative patients[J]. Ann Hematol, 2010, 89(3): 255-262. DOI: 10.1007/s00277-009-0806-7.
- [16] Kusumoto S, Arcaini L, Hong X N, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy[J]. Blood, 2019, 133(2): 137-146. DOI: 10.1182/blood-2018-04-848044.
- [17] Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb[J]. J Infect Chemother, 2005, 11(4): 189-191. DOI: 10.1007/s10156-005-0385-z.
- [18] Evens A M, Jovanovic B D, Su Y C, et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports[J]. Ann Oncol, 2011, 22(5): 1170-1180. DOI: 10.1093/annonc/mdq583.
- [19] Dong H J, Ni L N, Sheng G F, et al. Risk of hepatitis B virus (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituximab-chemotherapy: A meta-analysis[J]. J Clin Virol, 2013, 57(3): 209-214. DOI: 10.1016/j.jcv.2013.03.010.
- [20] Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab[J]. JAMA, 2013, 310(16): 1664. DOI: 10.1001/jama.2013.281115.
- [21] Bae S K, Gushima T, Saito N, et al. HBV reactivation after hematopoietic stem cell transplantation and rituximab-containing chemotherapy: A 12-year experience at a single center[J]. Bone Marrow Transplant, 2019, 54(4): 629-631. DOI: 10.1038/s41409-018-0355-6.
- [22] Lan T Y, Lin Y C, Tseng T C, et al. Risk of hepatitis B virus (HBV) reactivation in HBsAg-negative, anti-HBc-negative patients receiving rituximab for autoimmune diseases in HBV endemic areas[J]. Gut Liver, 2023, 17(2): 288-298. DOI: 10.5009/gnl210551.
- [23] Yang C M, Xie M X, Zhang K F, et al. Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection[J]. Leukemia, 2020, 34(11): 3055-3059. DOI: 10.1038/s41375-020-0913-y.
- [24] Wang Y, Liu Y, Tan X, et al. Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection[J]. Leukemia, 2020, 34(10): 2704-2707. DOI: 10.1038/s41375-020-0936-4.
- [25] Cao W Y, Wei J, Wang N, et al. Entecavir prophylaxis for hepatitis B virus reactivation in patients with CAR T-cell therapy[J]. Blood, 2020, 136(4): 516-519. DOI: 10.1182/blood.2020004907.
- [26] Liu W, Huang W Y, Wang M, et al. Risk of hepatitis B reactivation is controllable in patients with B-cell lymphoma receiving anti-CD19 CAR T cell therapy[J]. Br J Haematol, 2020, 191(1): 126-129. DOI: 10.1111/bjh.16951.
- [27] Cui R, Lyu C C, Li Q, et al. Humanized anti-CD19 chimeric antigen receptor-T cell therapy is safe and effective in lymphoma and leukemia patients with chronic and resolved hepatitis B virus infection[J]. Hematol Oncol, 2021, 39(1): 75-86. DOI: 10.1002/hon.2807.
- [28] Kong D Q, Ping N N, Gao X, et al. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: A retrospective study from a single center[J]. Front Immunol, 2023, 14: 1200748. DOI: 10.3389/fimmu.2023.1200748.
- [29] Fu S, Zhang Q Q, Jing R R, et al. HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy[J]. Bone Marrow Transplant, 2023, 58(6): 701-709. DOI: 10.1038/s41409-023-01960-2.
- [30] Tan J, Zhou J G, Zhao P, et al. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional

- disease-modifying antirheumatic drugs[J]. *Clin Rheumatol*, 2012, 31(8): 1169-1175. DOI: 10.1007/s10067-012-1988-2.
- [31] Ling W H, Soe P P, Pang A S, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours[J]. *Br J Cancer*, 2013, 108(10): 1931-1935. DOI: 10.1038/bjc.2013.225.
- [32] Ma B, Yeo W, Hui P, et al. Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer: A retrospective review of Chinese patients and comparison with an historic Western series [J]. *Radiother Oncol*, 2002, 62(2): 185-189. DOI: 10.1016/s0167-8140(02)00003-8.
- [33] Yeo W, Chan P K, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: A prospective study [J]. *J Med Virol*, 2003, 70(4): 553-561. DOI: 10.1002/jmv.10430.
- [34] Chen M, Zhuang J L, Zhou D B, et al. Outcome of anti-thymocyte immunoglobulin plus cyclosporine A for severe aplastic anaemia with chronic hepatitis B virus infection[J]. *Ann Hematol*, 2017, 96(4): 581-587. DOI: 10.1007/s00277-017-2918-9.
- [35] Zhang X Y, Zhou Y X, Chen C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. *J Immunother Cancer*, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5.
- [36] Lee P C, Chao Y E, Chen M H, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. *J Immunother Cancer*, 2020, 8(2): e001072. DOI: 10.1136/jitc-2020-001072.
- [37] Byeon S, Cho J H, Jung H A, et al. PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence[J]. *Cancer Med*, 2020, 9(7): 2352-2362. DOI: 10.1002/cam4.2868.
- [38] Pertejo-Fernandez A, Ricciuti B, Hammond S P, et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection[J]. *Lung Cancer*, 2020, 145: 181-185. DOI: 10.1016/j.lungcan.2020.02.013.
- [39] Wong G L, Wong V W, Hui V W, et al. Hepatitis flare during immunotherapy in patients with current or past hepatitis B virus infection [J]. *Am J Gastroenterol*, 2021, 116(6): 1274-1283. DOI: 10.14309/ajg.0000000000001142.
- [40] Aceituno L, Bañares J, Ruiz-Ortega L, et al. The low incidence of viral hepatitis reactivation among subjects on immunotherapy reduces the impact of suboptimal screening rate[J]. *Front Med*, 2022, 9: 916213. DOI: 10.3389/fmed.2022.916213.
- [41] Hagiwara S, Nishida N, Ida H, et al. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection[J]. *Hepatol Res*, 2022, 52(9): 754-761. DOI: 10.1111/hepr.13798.
- [42] Yoo S, Lee D, Shim J H, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment[J]. *Clin Gastroenterol Hepatol*, 2022, 20(4): 898-907. DOI: 10.1016/j.cgh.2021.06.019.
- [43] Lasagna A, Albi G, Maserati R, et al. Occult hepatitis B in patients with cancer during immunotherapy with or without chemotherapy: A real-life retrospective single-center cohort study[J]. *Front Oncol*, 2023, 13: 1044098. DOI: 10.3389/fonc.2023.1044098.
- [44] Chen Y M, Huang W N, Wu Y D, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: A real-world study[J]. *Ann Rheum Dis*, 2018, 77(5): 780-782. DOI: 10.1136/annrheumdis-2017-211322.
- [45] Harigai M, Winthrop K, Takeuchi T, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis[J]. *RMD Open*, 2020, 6(1): e001095. DOI: 10.1136/rmdopen-2019-001095.
- [46] Wang S T, Tseng C W, Hsu C W, et al. Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib [J]. *Int J Rheum Dis*, 2021, 24(11): 1362-1369. DOI: 10.1111/1756-185X.14217.
- [47] Shiah H S, Chen C Y, Dai C Y, et al. Randomised clinical trial: Comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma[J]. *Aliment Pharmacol Ther*, 2013, 37(1): 62-73. DOI: 10.1111/apt.12132.
- [48] Kim P S, Ho G Y, Prete P E, et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B[J]. *Arthritis Care Res*, 2012, 64(8): 1265-1268. DOI: 10.1002/acr.21654.
- [49] Padovan M, Filippini M, Tincani A, et al. Safety of abatacept in rheumatoid arthritis with serologic evidence of past or present hepatitis B virus infection[J]. *Arthritis Care Res*, 2016, 68(6): 738-743. DOI: 10.1002/acr.22786.
- [50] Chen M H, Lee I C, Chen M H, et al. Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease[J]. *Ann Rheum Dis*, 2021, 80(11): 1393-1399. DOI: 10.1136/annrheumdis-2021-220774.
- [51] Sorà F, Ponziani F R, Laurenti L, et al. Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors[J]. *Leuk Lymphoma*, 2017, 58(4): 993-995. DOI: 10.1080/10428194.2016.1219906.
- [52] Orlandi E M, Elena C, Bono E. Risk of hepatitis B reactivation under treatment with tyrosine-kinase inhibitors for chronic myeloid leukemia [J]. *Leuk Lymphoma*, 2017, 58(7): 1764-1766. DOI: 10.1080/10428194.2016.1260127.
- [53] Wang Y H, Liang J D, Sheng W H, et al. Hepatitis B reactivation during treatment of tyrosine kinase inhibitors-Experience in 142 adult patients with chronic myeloid leukemia[J]. *Leuk Res*, 2019, 81: 95-97. DOI: 10.1016/j.leukres.2019.05.001.
- [54] Lee Y H, Bae S C, Song G G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy[J]. *Clin Exp Rheumatol*, 2013, 31(1): 118-121.
- [55] Caporali R, Bobbio-Pallavicini F, Atzeni F, et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases[J]. *Arthritis Care Res*, 2010, 62(6): 749-754. DOI: 10.1002/acr.20130.
- [56] Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs[J]. *Mod Rheumatol*, 2011, 21(6): 621-627. DOI: 10.1007/s10165-011-0458-z.
- [57] Ye H, Zhang X W, Mu R, et al. Anti-TNF therapy in patients with HBV infection: Analysis of 87 patients with inflammatory arthritis[J]. *Clin Rheumatol*, 2014, 33(1): 119-123. DOI: 10.1007/s10067-013-2385-1.
- [58] Barone M, Notarnicola A, Lopalco G, et al. Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection[J]. *Hepatology*, 2015, 62(1): 40-46. DOI: 10.1002/hep.27716.
- [59] Papalopoulos I, Fanouriakis A, Kougkas N, et al. Liver safety of non-tumour necrosis factor inhibitors in rheumatic patients with past hepatitis B virus infection: An observational, controlled, long-term study[J]. *Clin Exp Rheumatol*, 2018, 36(1): 102-109.
- [60] Pereira R, Raposo I, Nery F, et al. Risk of hepatitis B virus reactivation in patients treated with anti-TNF α agents for immune-mediated inflammatory diseases[J]. *Actas Dermosifiliogr*, 2018, 109(3): 285-287. DOI: 10.1016/j.ad.2017.07.011.
- [61] Schwaneck E C, Krone M, Kreissl-Kemmer S, et al. Management of anti-HBc-positive patients with rheumatic diseases treated with disease-modifying antirheumatic drugs-a single-center analysis of 2054 patients[J]. *Clin Rheumatol*, 2018, 37(11): 2963-2970. DOI: 10.1007/s10067-018-4295-8.
- [62] Pauly M P, Tucker L Y, Szpakowski J L, et al. Incidence of hepatitis B virus reactivation and hepatotoxicity in patients receiving long-term treatment with tumor necrosis factor antagonists[J]. *Clin Gastroenterol Hepatol*, 2018, 16(12): 1964-1973. e1. DOI: 10.1016/j.cgh.2018.04.033.
- [63] Watanabe T, Fukae J, Fukaya S, et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients

- treated with biological disease-modifying antirheumatic drugs[J]. *Int J Rheum Dis*, 2019, 22(4): 574-582. DOI: 10.1111/1756-185X.13401.
- [64] Chen M H, Chen M H, Chou C T, et al. Low but long-lasting risk of reversal of seroconversion in patients with rheumatoid arthritis receiving immunosuppressive therapy[J]. *Clin Gastroenterol Hepatol*, 2020, 18(11): 2573-2581.e1. DOI: 10.1016/j.cgh.2020.03.039.
- [65] Sayar S, Kürbüz K, Kahraman R, et al. Risk of hepatitis B reactivation during anti-TNF therapy; evaluation of patients with past hepatitis B infection[J]. *Turk J Gastroenterol*, 2020, 31(7): 522-528. DOI: 10.5152/tjg.2020.19295.
- [66] Fidan S, Capkin E, Arica D A, et al. Risk of hepatitis B reactivation in patients receiving anti-tumor necrosis factor- α therapy[J]. *Int J Rheumatic Dis*, 2021, 24(2): 254-259. DOI: 10.1111/1756-185X.14034.
- [67] Alexopoulou A, Dourakis S P, Pandelidaki H, et al. Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine[J]. *J Med Virol*, 2006, 78(8): 1043-1046. DOI: 10.1002/jmv.20660.
- [68] Power J P, El Chaar M, Temple J, et al. HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus[J]. *J Hepatol*, 2010, 53(4): 780-787. DOI: 10.1016/j.jhep.2010.04.034.
- [69] Toscanini F, de Leo P, Calcagno G, et al. Hepatitis B reactivation in a HBsAg-negative, HBcAb-positive patient receiving fludarabine for the treatment of chronic lymphocytic leukaemia[J]. *Case Reports Hepatol*, 2011, 2011: 258791. DOI: 10.1155/2011/258791.
- [70] Busuttill D P, Chasty R C, Fraser M, et al. Delayed reactivation of hepatitis B infection after cladribine[J]. *Lancet*, 1996, 348(9020): 129. DOI: 10.1016/S0140-6736(05)64642-9.
- [71] Zingaropoli M A, Pasculli P, Iannetta M, et al. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study[J]. *Mult Scler J Exp Transl Clin*, 2022, 8(1): 20552173211065731. DOI: 10.1177/20552173211065731.
- [72] Karaca M, Tural D, Akar E, et al. Hepatitis B reactivation rate is higher undergoing some cytotoxic chemotherapy in patients with solid tumors: A large retrospective study[J]. *Chemotherapy*, 2018, 63(5): 247-252. DOI: 10.1159/000489789.
- [73] Papatheodoridis G V, Lekakis V, Voulgaris T, et al. Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion[J]. *J Hepatol*, 2022, 77(6): 1670-1689. DOI: 10.1016/j.jhep.2022.07.003.
- [74] Ahn S S, Jung S M, Song J J, et al. Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: Data from real-world experience[J]. *Yonsei Med J*, 2018, 59(3): 452-456. DOI: 10.3349/ymj.2018.59.3.452.
- [75] Kuo M H, Tseng C W, Lu M C, et al. Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing tocilizumab-containing treatment[J]. *Dig Dis Sci*, 2021, 66(11): 4026-4034. DOI: 10.1007/s10620-020-06725-1.
- [76] Rodríguez-Tajes S, Miralpeix A, Costa J, et al. Low risk of hepatitis B reactivation in patients with severe COVID-19 who receive immunosuppressive therapy[J]. *J Viral Hepat*, 2021, 28(1): 89-94. DOI: 10.1111/jvh.13410.
- [77] Foo H, Phan F, Bagatella M, et al. Risk of hepatitis B reactivation following baricitinib or tocilizumab for treatment of COVID-19[J]. *Eur J Clin Microbiol Infect Dis*, 2023, 42(6): 799-801. DOI: 10.1007/s10096-023-04599-5.
- [78] Carroll M B. The impact of biologic response modifiers on hepatitis B virus infection[J]. *Expert Opin Biol Ther*, 2011, 11(4): 533-544. DOI: 10.1517/14712598.2011.554810.
- [79] Ly K, Smith M P, Thibodeaux Q, et al. Dupilumab in patients with chronic hepatitis B on concomitant entecavir[J]. *JAAD Case Rep*, 2019, 5(7): 624-626. DOI: 10.1016/j.jdc.2019.05.007.
- [80] Bianchelli T, Campanati A, Sapieni C, et al. The effect of dupilumab in an HBV-HIV coinfecting atopic patient: A case report[J]. *Acta Dermatovenereol Alp Pannonica Adriat*, 2021, 30(2): 71-73.
- [81] Kridin K, Abdelghaffar M, Bieber K, et al. The real-world, long-term risk of infections associated with dupilumab in atopic dermatitis: A global cohort study[J]. *J Eur Acad Dermatol Venereol*, 2025, 39(12): 2069-2078. DOI: 10.1111/jdv.20724.
- [82] El Jamaly H, Eslick G D, Weltman M. Meta-analysis: Hepatitis B reactivation in patients receiving biological therapy[J]. *Aliment Pharmacol Ther*, 2022, 56(7): 1104-1118. DOI: 10.1111/apt.17155.
- [83] Katelani S, Fragoulis G E, Bakasis A D, et al. HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: A systematic review and meta-analysis[J]. *Rheumatology (Oxford)*, 2023, 62(SI3): SI252-SI259. DOI: 10.1093/rheumatology/kead243.
- [84] Chiu H Y, Hui R C, Huang Y H, et al. Safety profile of secukinumab in treatment of patients with psoriasis and concurrent hepatitis B or C: A multicentric prospective cohort study[J]. *Acta Derm Venereol*, 2018, 98(9): 829-834. DOI: 10.2340/00015555-2989.
- [85] Li Y, Dang L, Lv C Z, et al. The safety of ixekizumab in Chinese adults with moderate-to-severe plaque psoriasis: Analyses from a prospective, single-arm, multicenter, 12-week observational study[J]. *Drug Saf*, 2024, 47(7): 711-719. DOI: 10.1007/s40264-024-01427-3.
- [86] Androutsakos T, Dimitriadis K, Koutsompina M L, et al. Hepatitis B reactivation in PsA patients: An SLR and meta-analysis for IL-17, IL-23 and JAK inhibitors[J]. *Rheumatology (Oxford)*, 2025, 64(3): 935-942. DOI: 10.1093/rheumatology/keae445.
- [87] Duncan J R, Orłowski T J, Elewski B E. Safety of guselkumab in hepatitis B virus infection[J]. *Dermatol Online J*, 2019, 25(10): 13030/qt47h636rx.
- [88] Mortato E, Talamonti M, Marcelli L, et al. A long-term real-world safety study of guselkumab in patients with psoriasis who have infectious comorbidities, malignancies or heart disease: The EARLY study[J]. *Clin Exp Dermatol*, 2025, 50(9): 1786-1794. DOI: 10.1093/ced/llaf172.
- [89] Zhang H L, Wu C, Jin H Z. Successful treatment of etanercept- and adalimumab-resistant pyoderma gangrenosum with spesolimab, moderate-dose corticosteroids, and minocycline[J]. *Journal of Dermatological Treatment*, 2025, 36(1): 2451811. DOI: 10.1080/09546634.2025.2451811.
- [90] Jaroszewicz J, Pawłowska M, Simon K, et al. Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfecting patients treated with DAA[J]. *Expert Rev Anti Infect Ther*, 2020, 18(10): 1045-1054. DOI: 10.1080/14787210.2020.1782189.
- [91] Pawlotsky J M, Negro F, Aghemo A, et al. EASL recommendations on treatment of hepatitis C: Final update of the series[J]. *J Hepatol*, 2020, 73(5): 1170-1218. DOI: 10.1016/j.jhep.2020.08.018.
- [92] 中华人民共和国国家卫生健康委员会. 原发性肝癌诊疗指南(2024年版)[J]. *临床肝胆病杂志*, 2024, 40(5): 893-918. DOI: 10.12449/JCH240508.
- National Health Commission of the People's Republic of China. Standard for diagnosis and treatment of primary liver cancer (2024 edition)[J]. *J Clin Hepatol*, 2024, 40(5): 893-918. DOI: 10.12449/JCH240508.
- [93] Jang J W, Choi J Y, Bae S H, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma[J]. *J Hepatol*, 2004, 41(3): 427-435. DOI: 10.1016/j.jhep.2004.05.014.
- [94] Jang J W, Choi J Y, Bae S H, et al. A randomized controlled study of pre-emptive lamivudine in patients receiving transarterial chemo-lipiodolization[J]. *Hepatology*, 2006, 43(2): 233-240. DOI: 10.1002/hep.21024.
- [95] 蒋世海, 李万浪, 吕永昌, 等. 恩替卡韦联合肝动脉化疗栓塞术对肝癌合并乙肝患者的疗效及乙肝病毒再激活的影响[J]. *肿瘤药学*, 2018, 8(2): 215-218. DOI: 10.3969/j.issn.2095-1264.2018.02.20.
- Jiang Shihai, Li Wanlang, Lyu Yongchang, et al. Therapeutic effect of nucleotide drugs (entecavir) combined with TACE on hepatic carcinoma patients with HBV[J]. *Anti Tumor Pharm*, 2018, 8(2): 215-218. DOI: 10.3969/j.issn.2095-1264.2018.02.20.
- [96] Lau G K, Liang R, Chiu E K, et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: A case con-

- trolled study[J]. *Bone Marrow Transplant*, 1997, 19(8): 795-799. DOI: 10.1038/sj.bmt.1700744.
- [97] Lau G K K, He M L, Fong D Y T, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation[J]. *Hepatology*, 2002, 36(3): 702-709. DOI: 10.1053/jhep.2002.35068.
- [98] 陈瑶, 许兰平, 刘开彦, 等. HBsAg 阳性患者异基因造血干细胞移植后的临床研究[J]. *中华内科杂志*, 2008, 47(4): 316-319. DOI: 10.3321/j.issn: 0578-1426.2008.04.016.
- Chen Yao, Xu Lanping, Liu Kaiyan, et al. A clinical study of allo-hematopoietic stem cell transplantation in HBsAg positive leukemia [J]. *Chin J Intern Med*, 2008, 47(4): 316-319. DOI: 10.3321/j.issn: 0578-1426.2008.04.016.
- [99] Wu Y B, Chen Y, Zhu P P, et al. Effectiveness of prophylactic antiviral therapy in reducing HBV reactivation for HBsAg-positive recipients following allogeneic hematopoietic stem cell transplantation: A multi-institutional experience from an HBV endemic area[J]. *Ann Hematol*, 2022, 101(3): 631-641. DOI: 10.1007/s00277-021-04730-6.
- [100] Onozawa M, Hashino S, Izumiya K, et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse sero-conversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection[J]. *Transplantation*, 2005, 79(5): 616-619. DOI: 10.1097/01.tp.0000151661.52601.fb.
- [101] Mikulska M, Nicolini L, Signori A, et al. Hepatitis B reactivation in HBsAg-negative/HBcAb-positive allogeneic haematopoietic stem cell transplant recipients: Risk factors and outcome[J]. *Clin Microbiol Infect*, 2014, 20(10): O694-O701. DOI: 10.1111/1469-0691.12611.
- [102] Seto W K, Chan T S, Hwang Y Y, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study[J]. *Hepatology*, 2017, 65(5): 1451-1461. DOI: 10.1002/hep.29022.
- [103] 中华医学会血液学分会造血干细胞应用学组. 异基因造血干细胞移植后防治乙型肝炎病毒再激活中国专家共识(2023年版)[J]. *中华血液学杂志*, 2023, 44(6): 441-448. DOI: 10.3760/cma.j.issn.0253-2727.2023.06.001.
- Stem Cell Application Group, Chinese Society of Hematology, Chinese Medical Association. Chinese expert consensus on prevention of hepatitis B virus reactivation after allogeneic hematopoietic stem cell transplantation (2023) [J]. *Chin J Hematol*, 2023, 44(6): 441-448. DOI: 10.3760/cma.j.issn.0253-2727.2023.06.001.
- [104] Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome[J]. *Hepatology*, 1999, 29(1): 257-263. DOI: 10.1002/hep.510290123.
- [105] Berger A, Preiser W, Kachel H G, et al. HBV reactivation after kidney transplantation[J]. *J Clin Virol*, 2005, 32(2): 162-165. DOI: 10.1016/j.jcv.2004.10.006.
- [106] Yin S F, Zhang F, Wu J P, et al. Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis[J]. *PLoS Med*, 2023, 20(3): e1004196. DOI: 10.1371/journal.pmed.1004196.
- [107] Cholongitas E, Papatheodoridis G V, Burroughs A K. Liver grafts from anti-hepatitis B core positive donors: A systematic review[J]. *J Hepatol*, 2010, 52(2): 272-279. DOI: 10.1016/j.jhep.2009.11.009.
- [108] Saab S, Waterman B, Chi A C, et al. Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: A systematic review[J]. *Liver Transpl*, 2010, 16(3): 300-307. DOI: 10.1002/lt.21998.
- [109] European Association for the Study of the Liver. EASL clinical practice guidelines on liver transplantation[J]. *J Hepatol*, 2024, 81(6): 1040-1086. DOI: 10.1016/j.jhep.2024.07.032.
- [110] Hartwig M G, Patel V, Palmer S M, et al. Hepatitis B core antibody positive donors as a safe and effective therapeutic option to increase available organs for lung transplantation[J]. *Transplantation*, 2005, 80(3): 320-325. DOI: 10.1097/01.tp.0000165858.86067.a2.
- [111] Horan J L, Stout J E, Alexander B D. Hepatitis B core antibody-positive donors in cardiac transplantation: A single-center experience[J]. *Transpl Infect Dis*, 2014, 16(5): 859-863. DOI: 10.1111/tid.12280.
- [112] Fytilli P, Ciesek S, Manns M P, et al. Anti-HBc seroconversion after transplantation of anti-HBc positive nonliver organs to anti-HBc negative recipients[J]. *Transplantation*, 2006, 81(5): 808-809. DOI: 10.1097/01.tp.0000198585.51562.57.
- [113] Fong T L, Bunnapradist S, Jordan S C, et al. Impact of hepatitis B core antibody status on outcomes of cadaveric renal transplantation: Analysis of United network of organ sharing database between 1994 and 1999[J]. *Transplantation*, 2002, 73(1): 85-89. DOI: 10.1097/00007890-200201150-00016.
- [114] Huprikar S, Danziger-Isakov L, Ahn J, et al. Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management[J]. *Am J Transplant*, 2015, 15(5): 1162-1172. DOI: 10.1111/ajt.13187.
- [115] Khemichian S, Kahn J, Terrault N A. Use of hepatitis B virus-positive organs in organ transplantation[J]. *Clin Liver Dis*, 2021, 25(4): 841-857. DOI: 10.1016/j.cld.2021.06.009.
- [116] Shang J, Wang H, Sun J, et al. A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: A single-institutional experience[J]. *Bone Marrow Transplant*, 2016, 51(4): 581-586. DOI: 10.1038/bmt.2015.328.
- [117] Li H R, Huang J J, Guo H Q, et al. Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy[J]. *J Viral Hepat*, 2011, 18(12): 877-883. DOI: 10.1111/j.1365-2893.2010.01386.x.
- [118] Zhang L, Yang S Y, Yu Y F, et al. Prophylactic effect of tenofovir on viral reactivation in immunocompromised pregnant women living with hepatitis B virus[J]. *Hepatol Commun*, 2022, 6(9): 2431-2440. DOI: 10.1002/hep4.1994.
- [119] 中华医学会血液学分会, 中国抗癌协会淋巴瘤专业委员会, 中华医学会肝病学会. 淋巴瘤合并乙型肝炎病毒感染患者管理的中国专家共识[J]. *中华肝脏病杂志*, 2013, 21(11): 815-820. DOI: 10.3760/cma.j.issn.1007-3418.2013.11.005.
- Chinese Society of Hematology, Chinese Medical Association; Lymphoma Committee of China Anti-Cancer Association; Chinese Society of Hepatology, Chinese Medical Association. Consensus on the management of lymphoma in patients with hepatitis B virus infection [J]. *Chin J Hepatol*, 2013, 21(11): 815-820. DOI: 10.3760/cma.j.issn.1007-3418.2013.11.005.
- [120] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会. 靶向B细胞和浆细胞的CAR-T细胞治疗中防治乙型肝炎病毒再激活的中国专家共识(2021年版)[J]. *中华血液学杂志*, 2021, 42(6): 441-446. DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001.
- Chinese Society of Lymphoma, Chinese Anti-cancer Association; Chinese Society of Hematology, Chinese Medical Association. The consensus on the prophylaxis and treatment of HBV reactivation in B or plasma cell-directed CAR-T cell therapy(2021) [J]. *Chin J Hematol*, 2021, 42(6): 441-446. DOI: 10.3760/cma.j.issn.0253-2727.2021.06.001.
- [121] Nowicka A A, Szymanek-Pasternak A, Janocha-Litwin J, et al. A sleeping giant: Late HBV reactivation after rituximab-based chemotherapy despite correct prophylaxis[J]. *Int Med Case Rep J*, 2024, 17: 1063-1067. DOI: 10.2147/IMCRJ.S495506.
- [122] Nakaya A, Fujita S, Satake A, et al. Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA? [J]. *Leuk Res*, 2016, 50: 46-49. DOI: 10.1016/j.leukres.2016.09.014.
- [123] 刘燕娜, 樊蓉, 杨瑞峰, 等. 慢性HBV感染者血清HBV RNA检测及临床应用的专家共识[J]. *中华肝脏病杂志*, 2022, 30(5): 505-512. DOI: 10.3760/cma.j.cn501113-20220420-00214.
- Liu Yanna, Fan Rong, Yang Ruifeng, et al. Expert consensus on measurement and clinical application of serum HBV RNA in patients with chronic HBV infection[J]. *Chin J Hepatol*, 2022, 30(5): 505-512. DOI: 10.3760/cma.j.cn501113-20220420-00214.